OverviewSuggest Edit

Orphazyme develops therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases. The Company focuses on development of cell-protective properties of the heat shock response, a natural defense mechanism in various cells; and arimoclomol, an investigative medicinal product that regulates the production of other proteins in the cell. 

TypePublic
Founded2009
HQKøbenhavn, DK
Websiteorphazyme.com

Latest Updates

Employees (est.) (Jun 2020)114
Share Price (Oct 2020)KR68.8
Cybersecurity ratingAMore

Key People/Management at Orphazyme

Kim Stratton

Kim Stratton

Chief Executive Officer
Anders Vadsholt

Anders Vadsholt

Chief Financial Officer
Thomas Blaettler

Thomas Blaettler

Chief Medical Officer
Georges Gemayel

Georges Gemayel

Chairman of the Board
Martin Bonde

Martin Bonde

Board Member
Catherine Moukheibir

Catherine Moukheibir

Board Member
Show more

Orphazyme Office Locations

Orphazyme has offices in København, Chicago and Newton
København, DK (HQ)
Ole Maaløes Vej 3
Chicago, US
180 N LaSalle St #3475
Newton, US
Riverside Center, 275 Grove St #2, Auburndale
Show all (3)

Orphazyme Financials and Metrics

Orphazyme Revenue

DKK

Net income (H1, 2020)

(251.4m)

EBIT (H1, 2020)

(245.6m)

Market capitalization (19-Oct-2020)

2.4b

Closing stock price (19-Oct-2020)

68.8

Cash (30-Jun-2020)

610.4m

EV

1.9b
Orphazyme's current market capitalization is kr2.4 b.
Annual
DKKFY, 2018FY, 2019

General and administrative expense

35.1m50.5m

R&D expense

196.5m285.4m

Operating expense total

231.7m336.0m

EBIT

(231.7m)(336.0m)
Half Year
DKKH1, 2019H1, 2020

General and administrative expense

23.3m78.6m

R&D expense

141.7m167.0m

Operating expense total

165.1m245.6m

EBIT

(165.1m)(245.6m)
Annual
DKKFY, 2018FY, 2019

Cash

394.7m123.6m

Prepaid Expenses

14.2m13.4m

Current Assets

423.4m148.2m

PP&E

1.9m3.7m
Half Year
DKKH1, 2020

Cash

610.4m

Current Assets

638.2m

PP&E

4.2m

Total Assets

676.4m
Annual
DKKFY, 2018FY, 2019

Depreciation and Amortization

1.4k3.8k

Accounts Payable

5.9k(2.8k)

Cash From Operating Activities

(234.8k)(326.8k)

Purchases of PP&E

(743.0)(2.8k)
Half Year
DKKH1, 2019H1, 2020

Depreciation and Amortization

2.1k2.3k

Accounts Payable

(11.4k)37.4k

Cash From Operating Activities

(166.6k)(204.2k)

Purchases of PP&E

(1.1k)(1.2k)
DKKFY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Orphazyme Acquisitions / Subsidiaries

Company NameDateDeal Size
Orphazyme Schweiz GmbH
Orphazyme US, Inc

Orphazyme Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Orphazyme Online and Social Media Presence

Embed Graph

Orphazyme News and Updates

Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering

Orphazyme A/SCompany announcement                                                                                            No. 57/2020                                                                                                            Company Registration No. 32266355

Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe

Orphazyme A/SCompany announcement                                                                                            No. 55/2020                                                                                                          Company Registration No. 32266355

Orphazyme A/S provides update on previously announced global offering

Orphazyme A/SCompany announcement                                                                                       No. 54/2020                                                                                                          Company Registration No. 32266355

New incentive program for the Board of Directors of Orphazyme

Orphazyme A/SCompany announcement                                                                                       No. 53/2020                                                                                                          Company Registration No. 32266355

Orphazyme A/S commences a global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe

Orphazyme A/SCompany announcement                                                                                        No. 52/2020                                                                                                          Company Registration No. 32266355

Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C

Orphazyme A/SCompany announcement                                                                                       No. 50/2020                                                                                                           Company Registration No. 32266355
Show more

Orphazyme Frequently Asked Questions

  • When was Orphazyme founded?

    Orphazyme was founded in 2009.

  • Who are Orphazyme key executives?

    Orphazyme's key executives are Kim Stratton, Anders Vadsholt and Thomas Blaettler.

  • How many employees does Orphazyme have?

    Orphazyme has 114 employees.

  • Who are Orphazyme competitors?

    Competitors of Orphazyme include Rocket Pharmaceuticals, ARCA biopharma and Ultragenyx Pharmaceutical.

  • Where is Orphazyme headquarters?

    Orphazyme headquarters is located at Ole Maaløes Vej 3, København.

  • Where are Orphazyme offices?

    Orphazyme has offices in København, Chicago and Newton.

  • How many offices does Orphazyme have?

    Orphazyme has 3 offices.